Overview

• YCT-529’s Phase 1 trial enrolled 16 vasectomized men aged 32–59 to focus solely on safety and tolerability.
• Participants experienced no significant side effects, hormone shifts, mood changes or sexual dysfunction across doses from 10 mg to 180 mg.
• Pharmacokinetic data revealed rapid absorption and a two- to three-day half-life in blood, suggesting a once-daily regimen.
• The nonhormonal pill inhibits retinoic acid receptor-alpha by blocking a vitamin A metabolite in the testes to temporarily halt sperm production.
• YourChoice Therapeutics will launch larger Phase 2/3 trials to assess pregnancy prevention and optimal dosing as other male contraceptives like NES/T gel and ADAM implant advance.